The regulatory setback occurred when the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine, citing significant uncertainties in the company’s new drug application that require further evidentiary support. This rejection halted the anticipated progress of the bitopertin program, leading to a sharp devaluation for investors holding IRON shares.

Rosen Law Firm is now organizing a potential class action to recover investor losses, operating on a contingency fee basis. Shareholders who purchased securities before the announcement are encouraged to contact attorney Phillip Kim to participate in the litigation. While the firm touts a history of high-profile settlements and top-tier rankings in securities litigation, potential plaintiffs are reminded that prior legal successes do not guarantee a specific outcome in this case.